Capital Research Global Investors Vertex Pharmaceuticals Inc Transaction History
Capital Research Global Investors
- $479 Billion
- Q2 2025
A detailed history of Capital Research Global Investors transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Capital Research Global Investors holds 16,108,291 shares of VRTX stock, worth $6.25 Billion. This represents 1.5% of its overall portfolio holdings.
Number of Shares
16,108,291
Previous 14,536,344
10.81%
Holding current value
$6.25 Billion
Previous $7.05 Billion
1.76%
% of portfolio
1.5%
Previous 1.6%
Shares
20 transactions
Others Institutions Holding VRTX
# of Institutions
1,806Shares Held
239MCall Options Held
1.96MPut Options Held
1.13M-
Capital World Investors Los Angeles, CA28.7MShares$11.1 Billion1.94% of portfolio
-
Vanguard Group Inc Valley Forge, PA24MShares$9.3 Billion0.18% of portfolio
-
Black Rock Inc. New York, NY21.3MShares$8.26 Billion0.23% of portfolio
-
State Street Corp Boston, MA11.8MShares$4.57 Billion0.2% of portfolio
-
Jpmorgan Chase & CO New York, NY7.76MShares$3.01 Billion0.29% of portfolio
About VERTEX PHARMACEUTICALS INC
- Ticker VRTX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 256,691,008
- Market Cap $99.5B
- Description
- Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...